Meiji Seika Pharma initiates a Phase I trial in Australia evaluating ME3241, an anti-PD-1 agonist antibody discovered with FBRI.

Ohio Startup Opens Orders for At-Home Cognitive Enhancement Device While Advancing Separate Clinical Trials U's ...

These brain areas are also linked to impulsivity and emotional control in people with ADHD. By reducing food cravings and constant thoughts about eating, GLP⁠-1s may help some people feel more focused ...

Vitestro's ARPD blood-drawing robot gained an EU CE mark in 2024 and launched in the healthcare settings across the region in March 2025.

Oral TYK2 inhibitor deucravacitinib receives FDA approval for active psoriatic arthritis based on significantly improved ACR20 response rates.

PHILADELPHIA and VANCOUVER, British Columbia, March 10, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) ...

New data show bimekizumab is the first approved biologic to achieve superior outcomes in psoriatic arthritis vs an IL-23 inhibitor.

Treatments for Alzheimer disease agitation, focal segmental glomerulosclerosis, hematological malignancies, HIV-1, and obesity are under review.

Oral semaglutide reduces risk for heart failure events among patients with T2D and preexisting heart failure, according to the SOUL trial.

Povetacicept significantly reduced proteinuria in patients with IgA nephropathy in the RAINIER trial, supporting an upcoming FDA submission.

The Alliance for Clinical Trials in Oncology has launched a new clinical trial for adults who need first-line therapy for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The ...

Barclays 28th Annual Global Healthcare Conference March 11, 2026 9:30 AM EDTCompany ParticipantsSara Pellegrino ...